SCHEMBL19670596

SCHEMBL19670596

CCN1CCCN(C(=O)Nc2ccccn2)c2nc(N3CCC[C@H]3C(F)(F)F)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 1/20 0.40
▸ TRPV1 Q8NER1 1/20 0.37
▸ TRPA1 O75762 4/20 0.36
▸ PIK3C3 Q8NEB9 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ NTRK1 P04629 1/20 0.35
▸ CCNB2 O95067 1/20 0.35
▸ LCK P06239 1/20 0.35
▸ CDK1 P06493 1/20 0.35
▸ PDGFRB P09619 1/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ CDK4 P11802 1/20 0.35
▸ CCNB1 P14635 1/20 0.35
▸ FLT1 P17948 1/20 0.35
▸ CCNA2 P20248 1/20 0.35
▸ CCND1 P24385 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ CCNA1 P78396 1/20 0.35
▸ CDK6 Q00534 1/20 0.35
▸ CCNB3 Q8WWL7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19706163 1.00 FGFR4 (0.40) FGFR4TRPV1TRPA1PIK3C3JAK2
SCHEMBL19670627 1.00 FGFR4 (0.40) FGFR4TRPV1TRPA1PIK3C3JAK2
SCHEMBL19670345 0.89 FGFR4 (0.42) FGFR4TRPV1JAK2NTRK1CCNB2
SCHEMBL19706102 0.86 FGFR4 (0.40) FGFR4TRPV1SCN10A
SCHEMBL19670545 0.85 FGFR4 (0.40) FGFR4TRPV1NPC1TRPM8SCN10A
SCHEMBL19706295 0.85 FGFR4 (0.40) FGFR4TRPV1NPC1TRPM8SCN10A
SCHEMBL16775803 0.81 FGFR4 (0.48) FGFR4TRPV1NPC1ADORA2A
SCHEMBL19706272 0.78 TRPV3 (0.40) FGFR4SCN10A
SCHEMBL19670324 0.77 MAP4K4 (0.39) SCN10A
SCHEMBL19706161 0.77 TRPV3 (0.38) NPC1SCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2020-03-17 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 FGFR4 1754/4885TRPV1 3670/4885TRPA1 3603/4885
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators SIRT1, SIRT3, SIRT2 FGFR4 1754/4885TRPV1 3670/4885TRPA1 3603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback